Plus   Neg

Stock Alert: Inovio Pharma Falls 11%

Shares of Inovio Pharmaceuticals Inc. (INO) tanked 11% on Friday morning trade, ending a four-day growth streak.

The stock had on Thursday touched a 20-year high and gained more than 9-fold for a year-to-date period. The company on Tuesday had announced it secured a $71 million funding from the U.S. Department of Defense for the large-scale manufacture of its CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices, which are used to deliver the COVID-19 vaccine INO-4800 directly into the skin.

The company's COVID-19 vaccine candidate INO-4800 is also under a phase I study in the U.S., with interim results expected to be available later this month.

A phase II/III efficacy trial is planned to begin this summer (July/August).

INO is currently trading at $27.62, down $3.63 or 11.62%, on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT